|
|
|
|
|
 |
| |
| Saturday, April 4, 2009 |
|
Registration |
|
Welcome message |
|
| Prevalence & risk factors of COPD |
The prevalence and risk factors of COPD defined by post-bronchodilator GOLD criteria in Korea: the Korean Health & Genome Study
|
| (Chol Shin,Institute of Human Genomic Study, Korea University Ansan Hospital, Korea) |
|
|
| Pathogenesis of COPD & asthma with chronic airflow obstruction |
| Pathogenesis of COPD: genetic viewpoint |
| (Edwin Silverman, Harvard Medical School and Brigham & Women's Hospital, USA) |
Pathogenesis of COPD: pathobiologic viewpoint
|
| (William MacNee, University of Edinburgh /MRC Centre for Inflammation Research, The Queen's Medical Research Institute, UK) |
Pathogenesis of COPD : pathophysiologic viewpoint |
| (Won-Dong Kim, University of Ulsan College of Medicine and Asan Medical Center, Korea) |
| Break |
| Circulating fibroblast in asthma with chronic airflow obstruction |
| (Han-Pin Kuo, Chang Gung Univ. College of Medicine and Chang Gung Memorial Hospital, Taiwan) |
|
|
| Recent advances in evaluation of COPD & asthma |
Is post-bronchodilator FEV1/FVC less than 0.7 appropriate or overestimated for COPD diagnosis?
|
| (Sonia Buist, Pulmonary and Critical Care Medicine, Oregon Health & Science University, USA) |
| Lunch |
| Role of CT scan in evaluation of airway diseases: small airway disease of COPD & asthma |
| (Harvey O Coxson, RadiologyiCAPTURE Centre for Cardiovascular and Pulmonary ResearchVancouver General Hospital, Canada) |
| Functional Pulmonary Imaging for chronic obstructive lung disease |
| (Joon Beom Seo, Radiology, University of Ulsan College of Medicine and Asan Medical Center, Korea) |
|
|
| New aspects in chronic obstructive lung diseases |
| Vascular repair and COPD |
| (William MacNee, University of Edinburgh /MRC Centre for Inflammation Research, The Queen's Medical Research Institute, UK) |
COPD as a systemic disease - epidemiologic viewpoint
|
| (Sonia Buist, Pulmonary and Critical Care Medicine, Oregon Health & Science University, USA) |
| Break |
| Oxidative stress, particulate matter, airway disease |
| ( Andre Nel, Clinical Immunology and Allergy, UCLA Medical Center, Division of NanoMedicine, California NanoSystems Institute, USA) |
|
|
| Prevention of exacerbation & best care in COPD |
| Best care for preventing COPD exacerbation |
| (Peter Calverley, Respiratory Medicine at the University of Liverpool, UK) |
| Predictors of COPD exacerbation |
| (Masaharu Nishimura, Hokkaido University School of Medicine, Japan) |
| Mucolytics for prevention of COPD exacerbation |
| (Nanshan Zhong, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College, China) |
| Close |
|
|
| |
| |
| Sunday, April 5, 2009 |
|
Registration |
|
| Heterogeneity of airway diseases |
| Heterogeneity in COPD |
| (Sang- Do Lee, Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine and Asan Medical Center, Korea) |
| COPD phenotype & biomarker |
| (Frank C Sciurba, Emphysema/COPD Research Center Division of Pulmonary and Critical Care Medicine University of Pittsburgh, USA) |
Heterogeneity in response to treatment for asthmatics
|
| (Sang Heon Cho., Internal Medicine, Seoul National University College of Medicine, Korea.) |
| Break |
|
|
| Advances in therapy targeting airways & emphysema |
| New drugs targeting COPD airway |
| (Peter Calverley, Respiratory Medicine at the University of Liverpool, UK) |
| Bronchoscopic lung volume reduction targeting emphysema |
| (Frank C Sciurba, Emphysema/COPD Research Center Division of Pulmonary and Critical Care Medicine University of Pittsburgh, USA) |
Delivery devices in the future Nanovalve- controlled nanoparticle delivery devices |
( Andre Nel, Clinical Immunology and Allergy, UCLA Medical Center, Division of NanoMedicine, California NanoSystems Institute, USA) |
| Close |
|
|
| |
|
| |
|
|
